Mindset Pharma is a biotechnology company developing medications and synthesis processes for the medical psychedelic market
Download Presentation

1 in 4 people in the world will be affected by mental or neurological disorders in their life

20% of adults in the US have been diagnosed with depression as of 2017

37.1 million US adults received mental health treatment in 2018

The Opioid crisis is estimated to cost the US economy over $500 billion a year

4.9% of the world's adult population suffer from alcohol use disorder and 22.5% of adults in the world smoke tobacco products

It is evident that existing treatments are not working well enough and new innovative solutions are needed.

Get Into The Mindset

  • Classic psychedelics will likely be approved for medical use in the near future, however, they are not optimized as pharmaceuticals and cannot be patented as they are in the public domain 
  • Mindset is applying innovative medicinal chemistry to create a pipeline of optimized psychedelic medications with improved efficacy and reduced toxicity 
  • Mindset has developed a patent-pending chemical synthesis process to address a pressing need for scalable, pharmaceutical grade, low-cost psilocybin
Learn More

Let's Stay in Touch

Get the latest info and press releases delivered right to your inbox.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Press Releases & News

Mindset Pharma Announces Closing of $7.5 Million Bought Deal Public Offering

April 15, 2021

Read More

Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development

March 30, 2021

Read More

Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform ("Cope"); Cope Expected to Be World's First in Vivo Psychedelic Benchmark Data Set

March 23, 2021

Read More